RT Journal Article SR Electronic T1 Enrichment for Cases of African-American Patients with Pathogenic TTR V142I Variant in the TOPCAT Trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.14.20201046 DO 10.1101/2020.10.14.20201046 A1 Nikolaos Papoutsidakis A1 Neeru Gandotra A1 Edward Miller A1 Michael F. Murray A1 Curt Scharfe A1 Daniel Jacoby YR 2020 UL http://medrxiv.org/content/early/2020/10/16/2020.10.14.20201046.abstract AB Transthyretin cardiac amyloidosis (ATTR-CA) is a treatable cause of heart failure with a hereditary form that disproportionally affects patients of West African ancestry. The clinical management of ATTR-CA has dramatically changed in the past five years, with rapidly evolving diagnostic approaches and life-prolonging therapies. The TTR variant c.424G>A, p.V142I (aka V122I) is pathogenic and occurs in 3-4% of individuals of West African ancestry. Despite its high frequency, V142I ATTR-CA is often unrecognized due to variable clinical penetrance, limited knowledge, and lack of inexpensive non-invasive diagnostic tests. Currently unknown is which TTR V142I carriers will progress to heart failure and at what age. Here we studied the prevalence of TTR V142I among a random cohort of African-American patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Three of the 26 HFpEF patients (11.5%) studied carried the pathogenic TTR V142I variant. While we cannot conclude at this point that TTR V142I was the underlying cause of the clinical phenotype in these patients, our results suggest that rapid TTR V142I genotyping, in combination with heart imaging, could have immediate clinical utility for identifying under-/mis-diagnosed HFpEF patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN.a.Funding StatementThis work was in parts supported by institutional funds at Yale University and a Connecticut Innovations Biopipeline program award (CS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was overseen by the institutional review board at Yale University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are provided in Table 1.